Cetera Investment Advisers Acquires 494 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Cetera Investment Advisers grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 5.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 9,239 shares of the biopharmaceutical company's stock after purchasing an additional 494 shares during the period. Cetera Investment Advisers' holdings in Regeneron Pharmaceuticals were worth $6,581,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Capital International Investors grew its position in Regeneron Pharmaceuticals by 41.6% during the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock worth $3,373,859,000 after acquiring an additional 1,390,534 shares during the last quarter. Geode Capital Management LLC grew its position in Regeneron Pharmaceuticals by 6.8% during the 4th quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company's stock worth $1,726,940,000 after acquiring an additional 155,369 shares during the last quarter. Dodge & Cox grew its position in Regeneron Pharmaceuticals by 0.4% during the 4th quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company's stock worth $1,653,543,000 after acquiring an additional 9,381 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in Regeneron Pharmaceuticals by 63.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock worth $1,485,527,000 after acquiring an additional 810,144 shares during the last quarter. Finally, Franklin Resources Inc. grew its position in Regeneron Pharmaceuticals by 7.9% during the 4th quarter. Franklin Resources Inc. now owns 2,045,210 shares of the biopharmaceutical company's stock worth $1,456,864,000 after acquiring an additional 149,124 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on REGN shares. Canaccord Genuity Group upgraded Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, April 22nd. Wells Fargo & Company cut their target price on Regeneron Pharmaceuticals from $750.00 to $700.00 and set an "overweight" rating on the stock in a report on Wednesday, April 30th. The Goldman Sachs Group cut their target price on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. StockNews.com downgraded Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 1st. Finally, Royal Bank of Canada cut their target price on Regeneron Pharmaceuticals from $1,051.00 to $943.00 and set an "outperform" rating on the stock in a report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, eighteen have assigned a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $892.60.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $575.63 on Tuesday. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $62.93 billion, a price-to-earnings ratio of 15.04, a PEG ratio of 2.34 and a beta of 0.43. The stock has a 50 day moving average of $610.85 and a 200 day moving average of $690.93. Regeneron Pharmaceuticals, Inc. has a 12 month low of $520.50 and a 12 month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The business had revenue of $3.03 billion for the quarter, compared to analysts' expectations of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business's revenue was down 3.7% compared to the same quarter last year. During the same period in the previous year, the business posted $9.55 earnings per share. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.61%. The ex-dividend date of this dividend is Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.